By Tom Brockbank, Henrike Granzow and Alexandrosz Czira, GPI Current treatment options and target indications Malignant melanoma is the most lethal form of skin cancer1. In the UK approximately 15,400 new cases occur per year, and since the early 1990’s the incidence rate has more than doubled (128% increase)2. The incidence varies within Europe, from … More Combination therapy for melanoma: What are the current challenges in pricing & access from EU and US payers’ perspective?
Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, regional or local stakeholders and pharmaceutical companies being responsible for engaging in price formalities such as negotiations on a bilateral basis. But the landscape in Europe is beginning to show signs of change in how pricing … More Taking stock: European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations
Biosimilar launches of antineoplastic monoclonal antibodies represent a milestone in oncological care but also a new chapter in the application of biosimilars; introducing more prescribers, payers and stakeholders to the biological copies. Rituximab biosimilars came to the European market in 2017, while trastuzumab biosimilars have been keenly awaited since, and were first launched in the … More Biosimilars in Oncology: Trastuzumab is taking off
GPI LEAP creates a clear vision for the most ambitious talent by inspiring individuals from diverse backgrounds to come together, grow and succeed in an innovative and dynamic team. We are passionate about growing and developing a world-class, high-performing team of experts through our challenging programme. In an ever-changing global landscape, GPI LEAP shapes careers … More Learn – Engage – Apply – Perform! GPI has launched LEAP; our new career development & training programme
One of the advantages of working in a global consultancy and technology solutions firm such as Global Pricing Innovations (GPI), which specializes in pharmaceutical pricing, is the wide exposure one receives to the many different challenges across disease areas, companies, and geographies. This forces us all at GPI to keep on our toes and gives … More What will shape the global pharmaceutical pricing environment in 2018?
Canada’s plan to revise reference basket In a bid to reduce medicine prices in Canada, the Canadian Minister of Health announced the revision of the reference basket for international reference pricing (IRP). Medicines prices in Canada are regulated by the federal government, through the PMPRB (Patented Medicine Prices Review Board). The current reference rule used … More International Reference Pricing Reforms